Q2 2024 · 13F-HR
Deep Track Capital, LPholdings as filed
Filed 2024-08-14 · accession 0001856083-24-000003
$3.35B
Reported value
68
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 031162100 | AMGN | AMGEN INC | $179.7M | 5.36% | 575,000 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $172.0M | 5.13% | 400,000 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $149.1M | 4.45% | 1,852,784 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $141.2M | 4.21% | 4,000,000 | Common | SOLE |
| 85205L107 | SWTXUSD | SPRINGWORKS THERAPEUTICS INC | $139.4M | 4.16% | 3,700,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $134.0M | 4.00% | 2,000,000 | Common | SOLE |
| 40131M109 | GH | GUARDANT HEALTH INC | $130.0M | 3.88% | 4,500,000 | Common | SOLE |
| 268158201 | DVAX | DYNAVAX TECHNOLOGIES CORP | $122.4M | 3.65% | 10,900,000 | Common | SOLE |
| 02043Q107 | ALNY | ALNYLAM PHARMACEUTICALS INC | $121.5M | 3.63% | 500,000 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS INC | $107.4M | 3.21% | 4,800,000 | Common | SOLE |
| 46116X101 | ITCIEUR | INTRA-CELLULAR THERAPIES INC | $105.3M | 3.14% | 1,537,922 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $95.9M | 2.86% | 2,500,000 | Common | SOLE |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $95.3M | 2.85% | 2,000,000 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $87.0M | 2.60% | 12,721,460 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $85.2M | 2.54% | 4,061,401 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $84.3M | 2.52% | 3,500,000 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $83.3M | 2.49% | 3,991,500 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $76.1M | 2.27% | 2,883,736 | Common | SOLE |
| 088786108 | BCYC | BICYCLE THERAPEUTICS PLC | $70.6M | 2.11% | 3,490,506 | Common | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $64.2M | 1.92% | 5,972,257 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $60.6M | 1.81% | 7,370,000 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $57.8M | 1.73% | 4,000,000 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $55.3M | 1.65% | 4,179,763 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $55.1M | 1.65% | 13,000,000 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $53.1M | 1.59% | 15,272,172 | Common | SOLE |
| 88322Q108 | TGTX | TG THERAPEUTICS INC | $51.1M | 1.52% | 2,870,131 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $51.0M | 1.52% | 3,923,849 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $44.8M | 1.34% | 1,500,000 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $44.0M | 1.31% | 6,103,817 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $43.3M | 1.29% | 4,000,000 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $41.5M | 1.24% | 6,100,000 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $41.3M | 1.23% | 1,756,667 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $39.4M | 1.17% | 1,000,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $37.3M | 1.11% | 950,000 | Common | SOLE |
| 00182C103 | ANIP | ANI PHARMACEUTICALS INC | $29.7M | 0.89% | 466,089 | Common | SOLE |
| 28106W103 | EDIT | EDITAS MEDICINE INC | $28.0M | 0.84% | 6,000,000 | Common | SOLE |
| 28658R106 | CLYM | ELIEM THERAPEUTICS INC | $27.8M | 0.83% | 3,904,785 | Common | SOLE |
| 43157M102 | — | HILLEVAX INC | $26.5M | 0.79% | 1,832,652 | Common | SOLE |
| 500946108 | KRRO | KORRO BIO INC | $26.1M | 0.78% | 770,645 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $25.8M | 0.77% | 1,359,745 | Common | SOLE |
| 640268108 | NKTREUR | NEKTAR THERAPEUTICS | $22.2M | 0.66% | 17,875,498 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $21.2M | 0.63% | 2,250,000 | Common | SOLE |
| 014442107 | ALEC | ALECTOR INC | $21.0M | 0.63% | 4,631,998 | Common | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $18.4M | 0.55% | 2,294,011 | Common | SOLE |
| 31189P102 | FATE | FATE THERAPEUTICS INC | $18.3M | 0.55% | 5,572,607 | Common | SOLE |
| 45773H409 | INO | INOVIO PHARMACEUTICALS INC | $16.7M | 0.50% | 2,066,720 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $16.1M | 0.48% | 389,546 | Common | SOLE |
| 23256X100 | — | CYBIN INC | $15.8M | 0.47% | 58,139,535 | Common | SOLE |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $14.9M | 0.44% | 7,419,355 | Common | SOLE |
| 747324101 | PYXS | PYXIS ONCOLOGY INC | $13.8M | 0.41% | 4,184,100 | Common | SOLE |
| 00534A102 | IVVD | INVIVYD INC | $12.0M | 0.36% | 10,953,937 | Common | SOLE |
| G9TY5A101 | ZURA | ZURA BIO LTD | $11.5M | 0.34% | 3,283,783 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $7.9M | 0.24% | 384,756 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $7.2M | 0.21% | 132,495 | Common | SOLE |
| 75915K309 | RGLS | REGULUS THERAPEUTICS INC | $5.8M | 0.17% | 3,262,564 | Common | SOLE |
| 02157Q109 | ANRO | ALTO NEUROSCIENCE INC | $5.5M | 0.16% | 511,686 | Common | SOLE |
| 00847G804 | AGEN | AGENUS INC | $5.2M | 0.16% | 313,359 | Common | SOLE |
| 01671P100 | ALLKGUSD | ALLAKOS INC | $5.0M | 0.15% | 5,000,000 | Common | SOLE |
| 87184Q206 | SYRS | SYROS PHARMACEUTICALS INC | $4.3M | 0.13% | 828,485 | Common | SOLE |
| 75955J402 | RLMD | RELMADA THERAPEUTICS INC | $3.7M | 0.11% | 1,234,773 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $3.4M | 0.10% | 186,386 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $3.1M | 0.09% | 372,559 | Common | SOLE |
| 760273102 | RPTX | REPARE THERAPEUTICS INC | $3.0M | 0.09% | 904,261 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $2.6M | 0.08% | 308,235 | Common | SOLE |
| 92673K108 | VIGL | VIGIL NEUROSCIENCE INC | $2.4M | 0.07% | 597,215 | Common | SOLE |
| 01626L105 | — | ALIGOS THERAPEUTICS INC | $2.1M | 0.06% | 6,102,770 | Common | SOLE |
| 59102M104 | MGX | METAGENOMI INC | $1.9M | 0.06% | 466,232 | Common | SOLE |
| 640979100 | NMRA | NEUMORA THERAPEUTICS INC. | $1.8M | 0.05% | 180,500 | CALL | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.